Viyash Scientific Limited · NSE:VIYASH
Viyash Scientific — SeQuent Scientific — Q1 FY24 Earnings Presentation
13 slides from Viyash Scientific's earnings presentation, Aug 10, 2023
Slide 1: Proven Ability In Life Sciences
Proven Ability In Life Sciences August 10, 2023 BSE Limited National Stock Exchange of India Limited Corporate Relationship Department Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra‐Kurla Complex, Dalal Street, Fort, Bandra (East), Mumbai – 400 001. Mumbai – 400 051. Scrip code
Slide 2: Earnings Presentation Q1FY24
Earnings Presentation Q1FY24 10th August 2023 1
Slide 3: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "pl
Slide 4: Sequent Scientific – Q1 FY24 Earnings Release
Sequent Scientific – Q1 FY24 Earnings Release In line with our priority to improve margins, we have continued to make structural adjustments in our Formulations business. The streamlining of our European operations is nearly complete with the discontinuance of manufacturing operations in our Germany
Slide 5: Q1 FY24: Key Highlights
Q1 FY24: Key Highlights Europe portfolio reshaping Network optimization – on‐track Emerging Markets – Discontinued manufacturing Significant price hike in ops in Germany facility; tech Continuing improvement in Turkey to start reflecting transfer to Turkey / CMOs on‐ Gross margin and reduction towar
Slide 6: Q1 FY24: Revenue Performance – by geography
Q1 FY24: Revenue Performance – by geography All values in ₹ Mn QoQ Gr% YoY Gr% • Europe: Revenue Distribution Q1 FY24 Q4 FY23 QoQ Gr% Q1 FY23 YoY Gr% (In cc) (In cc) o Spain portfolio restructuring on‐ Formulations 2,478 2,559 (3.2%) (4.0%) 2,460 0.7% (2.1%) track; continuing improvement in Europe 1
Slide 7: Formulations Q1 FY24: Sustained performance in Europe and India; Turkey impacted
Formulations Q1 FY24: Sustained performance in Europe and India; Turkey impacted due to economic challenges Key Updates FDFs 1000+ EUROPE: • Portfolio reshaping ongoing – continuing improvement seen in Gross Margins • Discontinuance of Germany manufacturing operations; tech transfer to CMOs and Turk
Slide 8: API: Getting reshaped for profitable growth; on-track for sequential improvement in Q2
API: Getting reshaped for profitable growth; challenging quarter but on‐track for sequential improvement in Q2 Key Updates • In line with our network optimization objective, we discontinued manufacturing operations at the Commercial 30+ Tarapur plant; transitionary connectivity challenges led to rev
Slide 9: Financials
Financials NAS
Slide 10: Consolidated Financials
Consolidated Financials All values in ₹ Mn Particulars Q1 FY24 Q4 FY23 Q1 FY23 • Exceptional items: Revenue from Operations 3,332 3,667 3,413 Material Consumption (1,948) (2,217) (1,967) • INR 207mn pertains to Gross Margin 1,384 1,449 1,446 domain expert fees % 41.5% 39.5% 42.4% towards revamping o
Slide 11: Key Balance Sheet Items
Key Balance Sheet Items All values in ₹ Mn Particulars Jun‐23* Mar‐23* Shareholders’ Funds 6,240 6,981 Minority Interest 505 500 Net Debt 3,678 3,561 Investments 3 0 Tangible Assets 3,478 3,521 Intangible Assets 2,867 3,085 Working Capital 3,668 4,261 *Jun’23 & Mar’23 reported numbers are adjusted f
Slide 12: For details, feel free to contact
For details, feel free to contact: Krunal Shah Abhishek Singhal Nachiket Kale Company Secretary Investor Relations Consultant Investor Relations Advisor +91 22 4111 4779 abhishek.s@sequent.in +91 9920940808 investorrelations@sequent.in nachiket.kale@linkintime.co.in Registered Office: 301/A, ‘Dosti
Slide 13: Thank You
Thank You 12